Aurora-A (AURKA) is an exciting new drug target for the treatment of glioblastoma (GB). GB is a highly malignant, mostly adult brain tumor for which only marginal improvement in survival time has been achieved. AURKA is a serine-threonine kinase that drives mitotic progression and cytokinesis. It also positively regulates several proproliferative signaling pathways, including c-Myc, cyclin B/CDK1, NF-kB and Wnt signaling and negatively regulates p53. AURKA is oncogenic when overexpressed in cultured cells and its altered expression promotes genomic instability and malignancy. Our preliminary data show that the selective AURKA inhibitor MLN8237 potently inhibits proliferation of GB cells in vitro and extends animal survival in a GB orthotopic xenograft model. We will study the efficacy of MLN8237 against GB patient-derived neurosphere tumor stem-like cells in vitro, and in GB orthotopic xenograft mouse models using neurosphere stem-like cells from multiple patients. Alternate AURKA inhibitors and anti-AURKA RNAi will also be used to verify the efficacy of inhibiting this kinase and to distinguish off-target effects, respectively. These in vitro and animl studies will also investigate the possible synergistic effects of MLN8237 with other GB therapies, e.g., temozolomide, radiation, angiogenesis inhibitors and other chemotherapeutic drugs. We will perform experiments to determine if activated AURKA expression or candidate important interacting proteins, e.g., Bora and TPX2, predict sensitivity to MLN8237, an important step toward understanding which GB patients would likely benefit most from AURKA inhibition. We will determine the mechanisms of AURKA inhibition of tumor growth by examining effects of inhibitors on GB cell apoptosis, differentiation, senescence and genomic stability, as well as the regulation of biochemical pathways mediating these responses. Tumor hypoxia and angiogenesis are important mechanisms of tumor progression in gliomas. AURKA is induced by hypoxia and may itself increase angiogenic factors such as VEGF. We will study the effects of AURKA knockin and knockdown on important angiogenic signaling proteins, e.g., HIF-1?, GSK-3 and VEGF, in cultured cells to investigate possible direct and indirect roles of AURKA in GB angiogenesis. Since AURKA is induced by hypoxia we will test the ability of AURKA inhibitors to potentiate bevacizumab, which may potentially optimize the latter's clinical usefulness. We will also examine measurable biological effects of AURKA inhibition on angiogenesis, tumor invasion and genomic stability using in vitro and animal models.

Public Health Relevance

Glioblastoma is the most common type of brain cancer in adults. It is a very malignant tumor and most patients survive only about one year after diagnosis. Aurora-A inhibitors are a new type of chemotherapy drug that have shown promise against several types of cancer. The purpose of this grant proposal is to perform laboratory testing in cell cultures and mice to confirm that one of these new drugs is an effective weapon against glioblastoma. The ultimate goal of these studies is that this drug will be used to treat glioblastoma patients and allow them to survive longer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS081125-03
Application #
9125899
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Fountain, Jane W
Project Start
2014-09-01
Project End
2019-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
3
Fiscal Year
2016
Total Cost
$359,357
Indirect Cost
$126,008
Name
Ohio State University
Department
Pathology
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Zumbar, Cory T; Usubalieva, Aisulu; King, Paul D et al. (2018) The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells. J Neurooncol 137:481-492
Joehlin-Price, Amy S; Hardesty, Douglas A; Arnold, Christina A et al. (2017) Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease. Diagn Pathol 12:34
Kondo, Natsuko; Barth, Rolf F; Miyatake, Shin-Ichi et al. (2017) Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma. J Neurooncol 133:107-118
Lehman, Norman L; Hattab, Eyas M; Mobley, Bret C et al. (2017) Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. Neuro Oncol 19:31-42
Ceccarelli, Michele; Barthel, Floris P; Malta, Tathiane M et al. (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164:550-63
Georgescu, Maria-Magdalena; Mobley, Bret C; Orr, Brent A et al. (2016) NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors. Acta Neuropathol Commun 4:55
Usubalieva, Aisulu; Pierson, Christopher R; Kavran, Christina A et al. (2015) Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib. J Neuropathol Exp Neurol 74:960-9
Meisen, Walter Hans; Dubin, Samuel; Sizemore, Steven T et al. (2015) Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Mol Cancer Ther 14:307-14
Hong, Christopher S; Lehman, Norman L; Sauvageau, Eric (2014) A pilocytic astrocytoma mimicking a clinoidal meningioma. Case Rep Radiol 2014:524574
Van Brocklyn, James R; Wojton, Jeffrey; Meisen, Walter H et al. (2014) Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res 74:5364-70

Showing the most recent 10 out of 12 publications